Godrej Agrovet is a diversified agri-business with six segments: animal nutrition (feed), oil palm, crop protection, dairy, frozen foods, and Astec LifeSciences (agrochemicals and CDMO). In FY26 it generated consolidated revenue of ₹10,233 crores, with animal nutrition the largest contributor and oil palm the highest-return asset. The competitive structure varies by segment: animal feed is a large fragmented market but the company is gaining share with EBIT per tonne of ₹2,020 in Q3 FY26 and guided to ₹2,050-2,150; oil palm is a niche with few integrated players, and the company operates at an OER of 18.8% in Q1 FY27, backed by a plantation base that will roughly double to 150,000 hectares under the LRP. Astec, the life sciences arm, just reached EBITDA breakeven and has a CDMO margin profile about 1.5 times its enterprise business. The blended margin quality is visible in the 20% ROCE, which management has committed to protect, indicating that this is not a commodity business but a mix of asset-heavy plantation economics and high-margin specialty chemicals and branded retail.
The persistence of these economics comes from barriers that take years to replicate. Oil palm plantations require eight years from planting to peak productivity, and half of the existing trees are juvenile (0-4 years), meaning the demographic dividend is already embedded in the acreage. The company is adding 17,000 hectares per year, and its integrated Kannan complex, with nursery, CPO mill, and a specialty fats refinery that starts operations end August or early September 2026, will convert crude palm oil into value-added food ingredients, expected to add 200 basis points to group EBITDA once fully scaled. Astec's moat comes from owning triazole registrations in Europe and Brazil, backward integration for most enterprise molecules, and a CDMO inquiry funnel that doubled to 45; switching costs escalate once production processes are validated. In animal feed, the barrier is state-specific premium products and an expanding distribution network in East and Central India, while dairy benefits from 85-90% direct farm procurement. Crop care is the weakest link, still concentrated on cotton herbicide and chilli, but the launch of Ashitaka (maize) and Takai (paddy) plus two in-licensed products diversifies the portfolio.
The inflection point is now. Over the next 18-24 months, the business will look structurally different. Oil palm will see FFB tonnage grow at high single digit to early double digit as the juvenile trees mature and area expansion continues; the Khammam CPO plant is already live, and the specialty fats refinery will be fully ramped by H2 FY27, taking the oil palm portfolio to 50-55% value-added products by FY31. Astec is committed to at least 20% revenue growth in FY27 with CDMO at 50-52% of revenue, up from 48% in FY26, and management has guided to continued EBITDA positivity. Crop care is a recovery story: after a -16% revenue decline in Q1 FY27 due to a delayed monsoon, the company expects high double-digit growth from Q2 as the co-marketing inventory base clears and new products contribute 16-18% of revenue. Dairy is undergoing an 18-20 month route-to-market transformation that should lift value-added salience from 49% today toward higher levels, while Godrej Foods, now 32% B2C, is targeting 65-70% B2C over the LRP period. The consolidated picture for FY27 is double-digit revenue growth, mid-teens PBT growth, and a cash surplus of ₹100-125 crores after spending ₹350-400 crores on capex, with 75-80% of that growth capex and half going into oil palm.
Management has a mixed but largely positive walk-talk record. They delivered on Astec's FY26 EBITDA breakeven ahead of schedule, with Q3 revenue up 33% against a 20% annual target, and animal feed EBIT per tonne came in at the high end of guidance. However, the Khammam CPO plant was promised to go live within two months from February 2026 but actually rolled out only in the month before the August 2026 call, a slippage of several months; the downstream refinery also slipped from Q1 FY27 to end August or early September. Guidance has been maintained, with the FY27 consolidated PBT growth now described as confident of double-digit rather than the earlier mid-teens, while Astec's revenue growth target was raised from 15% to at least 20%. On capital allocation, the company is funding growth internally, expecting a cash surplus after capex, and has completed the acquisition of the remaining minority stake in Creamline Dairy. The portfolio strategy deep work, promised for early April 2026, has not yet produced a public communication, so the exit or restructuring of shrimp, seeds, cattle genetics, and live bird remains under review.
The earnings path is quantifiable. FY26 PBT ex-exceptionals was ₹569 crores, and mid-teens growth puts FY27 PBT in the range of ₹650-660 crores, with consolidated revenue moving from ₹10,233 crores toward ₹11,500 crores, driven by volume-led animal feed (cattle feed volumes up 15% in Q1), oil palm FFB growth, and crop care recovery from Q2. The operating leverage is visible: animal feed EBIT/ton is stable, oil palm downstream adds 200 bps, and Astec's CDMO mix lifts margins. The key falsifier is the monsoon: a below-normal or El Niño-affected season could hit crop care volumes and oil palm FFB, despite the demographic offset. Also, milk procurement prices are expected to stay elevated for two to three quarters, which will keep dairy margins under pressure until the route-to-market transformation kicks in. The tension between Q1 crop care revenue decline and the full-year recovery guidance is operational, not structural, because the base effect from co-marketing inventory clears after Q4 FY26 and the new product pipeline is on track. The single most important watchpoint is the timely scaling of the specialty fats refinery, as its 200 bps EBITDA contribution is the margin bridge that turns a good business into a high-return compounder.
companyname: Godrej Agrovet Limited ticker: GODREJAGRO sector: Diversified Agri-business (Animal Nutrition, Crop Care, Oil Palm / Vegetable Oil, Dairy, Poultry & Processed Foods, Agrochemicals CDMO) Godrej Agrovet Limited (GODREJAGRO) is the agri-business arm of the Godrej Industries Group, which traces to 1897. It is a diversified platform that touches Indian agriculture at several points: it sells inputs to farmers (crop protection chemicals, animal feed), sources and processes their output (...
Read the full report →capex, margin expansion, management upgrade
FY27 consolidated revenue growth guided at double-digit driven by volume-led growth across segments; PBT growth targeted at mid-teens
Guidance maintainedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Godrej Agrovet Limited and 4,900+ companies.
5-day free pass. No card required.